Shares of Bristol Myers Squibb Co. BMY slid 1.43% to $57.38 Wednesday, on what proved to be an all-around mixed trading ...

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions.

Approvals last year included rare disease treatments, new oncology drugs, Eli Lilly’s Kisunla, and Mesoblast's Ryoncil.

We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Rajiv Onat, India head, digital technology and engineering, Regeneron, acknowledged Telangana’s role in creating a ...

I always find myself rooting not necessarily for the actor who gave the best performance — because, really, who can say which ...

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...